Replies to post #15996 on The Rising Influence of Rising Affluence

[DewDiligence]

Yes on all counts. ABT is perhaps the ultimate ‘TGDT’ pick for conservation of capital plus steady growth.

[DewDiligence]

ABT director bought $4.2M of stock yesterday:

https://www.sec.gov/Archives/edgar/data/1800/000117911018003061/xslF345X03/edgar.xml
https://www.sec.gov/Archives/edgar/data/1800/000117911018003062/xslF345X03/edgar.xml
https://www.sec.gov/Archives/edgar/data/1800/000117911018003063/xslF345X03/edgar.xml

[DewDiligence]

ABT—1Q18 sales of branded generics +7% YoY in constant currency (+10% YoY in USD), led by >10% increases in India, China, and Brazil:

http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNjk3MzV8Q2hpbGRJRD02OTE5NzA=

The stock is off slightly today because ABT did not raise 2018-full-year (non-GAAP) EPS guidance; it remains $2.80-2.90.

[DewDiligence]

(ABT)—India’s 1Q18 GDP-growth clocks in at 7.7%:

https://www.wsj.com/articles/indias-economic-expansion-outpaces-rival-china-1527779172

ABT has the #1 market share of pharmaceuticals in India, although the market is highly fragmented.